Rocket Pharmaceuticals Announces Update on FDA Review Timeline of KRESLADI™ (marnetegragene autotemcel) for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I)

New Prescription Drug User Fee Act date of June 30, 2024

...

Related Keywords

California ,United States ,State Of California ,Medioambientalesy Tecnol ,Investigaciones Energ ,Gaurav Shah ,Enfermedades Raras ,Drug Administration ,California Institute For Regenerative Medicine Grant Number ,Linkedin ,Rocket Pharmaceuticals Inc ,Youtube ,University College London ,Nasdaq ,Rocket Pharmaceuticals ,Priority Review ,Biologics License Application ,Leukocyte Adhesion Deficiency I ,Chief Executive Officer ,Medicine Advanced Therapy ,Rare Pediatric ,Fast Track ,Advanced Therapy Medicinal Product ,Orphan Drug ,Centro De Investigaciones Energ ,Centro De Investigaci ,Red De Enfermedades Raras ,Instituto De Investigaci ,Sanitaria Fundaci ,California Institute ,Regenerative Medicine ,Grant Number ,Fanconi Anemia ,Pyruvate Kinase Deficiency ,Danon Disease ,Private Securities Litigation Reform Act ,Annual Report ,Quarterly Reports ,Markets ,